Compare ACRE & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACRE | TRDA |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 261.9M | 268.6M |
| IPO Year | 2011 | 2021 |
| Metric | ACRE | TRDA |
|---|---|---|
| Price | $4.66 | $6.95 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $5.38 | ★ $21.00 |
| AVG Volume (30 Days) | ★ 471.2K | 299.4K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 11.58% | N/A |
| EPS Growth | ★ 26.17 | N/A |
| EPS | ★ 1.35 | N/A |
| Revenue | ★ $54,833,000.00 | $25,421,000.00 |
| Revenue This Year | N/A | $39.97 |
| Revenue Next Year | $16.28 | $50.80 |
| P/E Ratio | $3.43 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.14 | $5.02 |
| 52 Week High | $5.89 | $16.45 |
| Indicator | ACRE | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 51.17 | 49.66 |
| Support Level | $4.60 | $5.71 |
| Resistance Level | $4.69 | $7.95 |
| Average True Range (ATR) | 0.10 | 0.41 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 42.40 | 37.37 |
Ares Commercial Real Estate Corp is a specialty finance company and a real estate investment trust mainly engaged in originating and investing in commercial real estate (CRE) loans and related investments. It operates in one segment, namely originating and managing a diversified portfolio of CRE debt-related investments. The company recognizes the majority of its revenues in the form of interest income, which it receives from loans.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.